Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings.

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company ...

MADRID (Reuters) -A New York court has found enough evidence to proceed with a defamation lawsuit filed by Grifols against ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Grifols, S.A. (NASDAQ:GRFS) is a company that unfortunately has not been performing as I expected it to. My position is in the green, but this has more to do with FX and me adding shares below my ...

Grifols (GRFS) said: “Grifols remains focused on the continued execution of its strategic plan and reaffirms its guidance for FY2025.Due to the impact of the Inflation Reduction Act on its ...

Grifols GRF-0.39%decrease; red down pointing triangle said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks for a 6.45 billion-euro ...

The Grifols family has held "very preliminary talks" through several investment firms over a potential takeover bid, according to a source close to the pharmaceutical company's reference shareholders.

In response, Grifols, a global leader in plasma science and the production of plasma-derived medicines, has embarked on a groundbreaking program in partnership with The Michael J. Fox Foundation ...

Spanish drugmaker Grifols SA, the target of a short-seller attack earlier in the year, is seeking to hire an external consultancy firm to help deal with minority investors as it faces a takeover ...